Regeneron

Company

Investment-firm

Last deal

$2.03M

Amount

Post-IPO Equity

Stage

11.07.2024

Date

3

all rounds

$341.93M

Total amount

Financing round

General

About Company
Regeneron Pharmaceuticals invents life-transforming medicines for people with serious diseases..

Industry

Sector :

Subsector :

founded date

01.01.1988

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Regeneron has several marketed products, including Eylea, Praluent, Dupixent, Libtayo, and Kevzara, and is currently developing products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company believes that when the right idea finds the right team, powerful change is possible, and they are committed to discovering, inventing, and developing biopharmaceutical medicines to create whole new ways of thinking about health. Regeneron was founded in 1988 and is headquartered in New York, USA.
Contacts

Phone number

Social url

Similar Companies
999
Gilead Sciences

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative medicines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Biopharma

Location

Foster City, CA, USA

total rounds

4

total raised

$4.41B

count Of Investments

62

count Of Exists

1
Apellis Pharmaceuticals

Apellis Pharmaceuticals

Apellis Pharmaceuticals develops therapeutics for chronic inflammatory lung diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Waltham, MA, USA

total rounds

11

total raised

$643.53M
Plexxikon

Plexxikon

Plexxikon is a developer of small molecule pharmaceuticals.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Berkeley, CA, USA

total rounds

3

total raised

$80.35M
Mitochon Pharmaceuticals

Mitochon Pharmaceuticals

Mitochon Pharmaceuticals is developing drugs targeting mitochondria for serious diseases with unmet medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Radnor, PA 19087, USA

total rounds

3

total raised

$2.33M

Financials

Funding Rounds
4
3

Number of Funding Rounds

$341.93M

Money Raised

Their latest funding was raised on 11.07.2024. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA)

BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical, Biotechnology

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

64

count Of Exists

2
Investments
9
Date 
name 
Lead 
type 
Raised 
Sonoma BioTherapeutics

Sonoma BioTherapeutics

Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

South San Francisco, CA, USA

total rounds

5

total raised

$410M
Enlaza Therapeutics

Enlaza Therapeutics

Enlaza Therapeutics is a California-based biotechnology research company that is pioneering the field of covalent biologics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

La Jolla, San Diego, CA, USA

total rounds

3

total raised

$165.02M
Sonoma BioTherapeutics

Sonoma BioTherapeutics

Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

South San Francisco, CA, USA

total rounds

5

total raised

$410M
Co-Investors
Investors
2
2

Number of lead investors

2

Number of investors

Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA)

BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical, Biotechnology

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

64

count Of Exists

2
U.S. Department of Health & Human Services

U.S. Department of Health & Human Services

The U.S. Department of Health & Human Services promotes the health and well-being of Americans through effective health and human services.

Sector

Health Care Providers

Subsector

Health Care Services

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

97

count Of Exists

5
Acquisitions
2
Acquiree Name 
Date 
Price 
Acquisition Name 
Decibel Therapeutics acquired by Regeneron

Decibel Therapeutics acquired by Regeneron

acquirer

Regeneron
Regeneron

date

09.08.2023

type

Acquisition

price

$213M
Decibel Therapeutics

Decibel Therapeutics

Decibel Therapeutics is a biotechnology company developing treatments for hearing and balance disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Cambridge, MA, USA

total rounds

5

total raised

$189.2M
Checkmate Pharmaceuticals acquired by Regeneron

Checkmate Pharmaceuticals acquired by Regeneron

acquirer

Regeneron
Regeneron

date

19.04.2022

type

Acquisition

price

$250M
Checkmate Pharmaceuticals

Checkmate Pharmaceuticals

Checkmate Pharma is a clinical-stage biopharmaceutical company that develops a new approach for cancer immunotherapy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Cambridge, MA, USA

total rounds

5

total raised

$170M

People

Founders
3
Leonard S. Schleifer
Leonard S. Schleifer

Leonard S. Schleifer

Leonard S. Schleifer, M.D., Ph.D., founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. From 1984 to 1988 he was Assistant Professor at the Cornell University Medical College in the Departments of Neurology and Neurobiology. Leonard Schleifer received his M.D. and Ph.D. in Pharmacology from the University of Virginia. Leonard Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology.

current job

Regeneron
Regeneron

organization founded

1

Leonard S. Schleifer

George D. Yancopoulos
George D. Yancopoulos

George D. Yancopoulos

George D. Yancopoulos, M.D., Ph.D., joined the Company in 1989 as its Founding Scientist and is currently President, Regeneron Laboratories and Chief Scientific Officer. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's three FDA-approved drugs - including EYLEA® (aflibercept) Injection, ZALTRAP Injection for Intravenous Infusion, and ARCALYST (rilonacept) Injection - as well as of its foundation technologies including the TRAP technology, VelociGene, and VelocImmune.

current job

Regeneron
Regeneron

organization founded

1

George D. Yancopoulos

Eric Shooter
Eric Shooter

Eric Shooter

Eric Shooter is a professor of neurobiology at the Stanford University School of Medicine. His research has dealt largely with understanding how nerves grow. He is perhaps best known discovering the protein known as nerve growth factor, which plays a key role in regrowing lost or damaged nerve cells. The discovery could someday make it possible to regrow nerves for those who have suffered spinal cord injuries, or to reverse the nerve degeneration that leads to Alzheimer's and Parkinson's diseases. Additionally, Shooter has researched the structure and mechanisms of neurotrophins, the proteins that keep nerve cells alive. He also discovered the gene in mice underlying a group of diseases called the demyelinating peripheral neuropathies in which the protective covering on nerves breaks down and the nerves are unable to function properly. The diseases are similar to human neurological diseases, and the discovery lays the groundwork for understanding how nerves repair themselves. Shooter obtained his PhD in chemistry in 1950 from the University of Cambridge and carried out his postdoctoral fellowship at the University of Wisconsin with J.W. Williams. Shooter was appointed as the USHS International Fellow with the Department of Biochemistry at Stanford in 1961. He was appointed associate professor of genetics and later as professor of biochemistry, and chaired the school's neurosciences PhD program. He served as chair of the Department of Neurobiology from 1975-87. Shooter has received numerous honors, including election to the Royal Society, London; Javits Neuroscience Investigator Award, NINDS; election to the American Academy of Arts and Sciences; the Ralph W. Garard Prize; Society of Neuroscience (shared with H. Thoenen) and was the Bristol-Myers Squibb Award winner for Distinguished Achievement in Neuroscience Research (shared with H. Thoenen).

current job

Regeneron
Regeneron

organization founded

1

Eric Shooter

Employee Profiles
1217
Michael Burczynski

Michael Burczynski

Senior Director, Precision Medicine

Vera Mastey

Vice president, health economics and outcomes research

Thomas Triolo

Senior director

Rick Ulloa

Associate director ngs lims

Kyra Goldsmith

Consultant

Bryan Harper

Senior director, market access product and pipeline strategy

Sarah Drabick

Senior specialist, corporate communications

Vinay Desai

Senior director research and development it

Activity

Recent News
43
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week